1. Introduction {#s0005}
===============

Whole exome sequencing (WES) is a powerful tool that can be utilized for the identification of pathogenic mutations. However it can also identify variants unrelated to phenotype. Here, we present a patient identified to have multiple mutations by WES that more effectively describe their complex phenotype than a single change.

Our patient initially came to attention for dilated cardiomyopathy (DCM) but also had a history of sensorineural hearing loss. Her clinical course was complicated as she had required extracorporeal membrane oxygenation (ECMO) on several occasions without a clear precipitating event. Her cardiac and family history prompted concern that there may be more than one cause for her findings. However extensive previous testing had been non-diagnostic, so WES was performed during a particularly serious and protracted hospital admission. Initial WES interpretation implicated genes associated with DCM, long QT syndrome (LQTS) in addition to multiple variants. Mitochondrial DNA sequencing identified a transfer RNA variant.

Typically, DCM can present with heart failure, cardiac arrhythmias or sudden cardiac death in an otherwise seemingly healthy individual. It has an estimated prevalence of 36 per 100,000 individuals and 25--30% of those cases are familial [@bb0005], [@bb0010], [@bb0015]. Inheritance patterns may be autosomal dominant, autosomal recessive, X-linked or mitochondrial. Massive parallel sequencing technologies have allowed the identification of the responsible gene in up to 40% of cases of familial DCM, making possible the screening of asymptomatic at-risk individuals [@bb0020], [@bb0025], [@bb0030].

LQTS is another leading cause of sudden cardiac death in children and its prevalence has been estimated to be as high as 1 in 2000 [@bb0035]. Gene sequencing panels currently available can identify mutations in 75% of patients with congenital LQTS [@bb0020].

Although the prevalence of congenital LQTS in families with DCM has not been studied, both conditions are most commonly inherited in an autosomal dominant manner. The contribution of a change in mitochondrial transfer RNA and LQTS in the context of a DCM variant of unknown significance could have potentiated a fatal scenario.

2. Case presentation {#s0010}
====================

A 4 year old girl with sensorineural hearing loss and speech delay initially presented to the emergency room due to breathing difficulty. Physical exam revealed a non-dysmorphic appearance with evidence of cardiovascular compromise and generalized hypotonia. Dilated eye exam was normal. Family history was significant for an older sister with speech delay and hearing loss who passed suddenly at age 2 years. The autopsy interpreted her death secondary to myocarditis, presumed to be of viral etiology. Both parents and two younger sisters were reportedly healthy although none had been evaluated formally for hearing or cardiac concerns. Two older paternal half-sisters were also reportedly healthy.

Upon admission, an echocardiogram revealed dilated cardiomyopathy (DCM). Endomyocardial biopsy showed no signs of myocarditis, negative viral DNA/RNA (adenovirus, CMV, EBV, enterovirus, parvovirus) and mild to moderate subendothelial fibrosis. Skeletal muscle biopsy was normal and included histochemical stains for mitochondrial oxidative phosphorylation defects (cytochrome C oxidase and succinate dehydrogenase), and analysis for ragged red fibers. Biochemical analyses to include plasma amino acids, urine organic acids, an acylcarnitine profile, and total and free carnitine were also normal.

During this initial presentation and hospitalization, the patient required extracorporeal membrane oxygenation (ECMO) with a left ventricular assist device (LVAD) and was evaluated for heart transplantation, but her cardiac function recovered prior to the anticipated surgery ([Fig. 1](#f0010){ref-type="fig"}). During the next four years, she was hospitalized five more times with acute heart failure and decompensation. Additional molecular genetic testing completed during these hospitalizations included chromosomal oligoarray (GeneDx, 2011), dilated cardiomyopathy sequencing panel (GeneDx, 2011, 27 genes), connexin 26 and connexin 30, Otoscope panel (University of Iowa 2012, 66 genes), were all non-diagnostic. The contents of each of these studies are listed in [Appendix A](#s0030){ref-type="sec"}.

Her average length of hospital stay was 41 days and after prolonged periods of cardiac and nutritional support she would fully recover to cardiac baseline. One prolonged hospitalization with apparent end organ failure required over three months of ECMO therapy. The chronicity and severity of these episodes were unusual particularly with the family history of sudden death and sensorineural hearing loss, and more aggressive molecular analysis was pursued.

3. Molecular diagnostics {#s0015}
========================

Whole exome sequencing (WES) inclusive of mitochondrial DNA testing targeting 162 nuclear and 37 mitochondrial genes (Baylor College of Medicine/MitomeNGSSM) was requested and revealed a maternally inherited "pathogenic" mutation in MYBPC3 and a likely pathogenic mutation in KCNH2 that was paternally inherited. Pathogenicity was determined by Mercury 1.0 (Baylor) [@bb0040]. All reported mutations and variants are listed in [Table 1](#t0005){ref-type="table"} and [Appendix A](#s0030){ref-type="sec"}. The MYBPC3 mutation was later reclassified as a variant of unknown significance (VUS).

Our patient also had an apparently homoplasmic mutation affecting the mitochondrial transfer RNA Cysteine (tRNA Cys) that was interpreted as pathogenic ([Table 1](#t0005){ref-type="table"} and [Appendix A](#s0030){ref-type="sec"}).

Neither one of the parents nor other older relatives had a known history of cardiac disease (Pedigree in [Appendix B](#s0035){ref-type="sec"}). The family was informed of the testing results and extensive genetic counseling was provided. The patient eventually died at 8 years of age after decompensation following a sudden illness. One of the patient\'s younger sisters was subsequently diagnosed with sensorineural hearing loss and developmental delay. Serial echocardiogram and EKG analyses have been normal, and she has never been hospitalized. Recent molecular testing showed that she has the same change in mitochondrial tRNA Cys in addition to the MYBPC3 variant. Testing of her deceased older sister was not able to be completed.

4. Discussion {#s0020}
=============

The combination of hearing loss and cardiomyopathy, in our patient and her deceased sister, suggested an underlying genetic etiology. However the initially available tools for genetic testing failed to provide a diagnosis until massive parallel sequencing of the entire exome became available.

Common causes of dilated cardiomyopathy in children include myocarditis, infiltrative disease and drugs. Approximately 50% of cases are considered idiopathic of which 20--50% are thought to be familial, depending on the screening methods used [@bb0015], [@bb0045]. Our patient was found to have a likely pathogenic mutation in the MYBPC3 gene, usually associated with hypertrophic cardiomyopathy (40%), but also reported in 4% of patients with familial or idiopathic dilated cardiomyopathy [@bb0050]. It was not reported abnormal in the initial cardiomyopathy panel ordered for this patient although included.

Interestingly, WES also revealed a mutation in KCNH2 associated with LQTS type 2 [@bb0055]. Although, we have no evidence of long QT in our patient, individuals with mutations in KCNH2 are at increased risk of sudden cardiac death, even in the absence of electrocardiographic abnormalities [@bb0060], [@bb0065].

Mitochondrial genome sequencing was ordered concurrently to consider an explanation to the patient\'s hearing loss, initial presentation of hypotonia, and severe recurrent episodes of heart failure. Mitochondrial disease can be secondary to alterations in mitochondrial proteins, which in turn can be encoded by nuclear or mtDNA [@bb0070]. Many mitochondrial mutations also affect the tRNA genes. Pathogenic mutations have been reported in 1 in 200 live births, however the prevalence of mitochondrial disorders is about 1 in 10,000 [@bb0075]. In general, mitochondrial disease refers to disorders of the respiratory chain, which tend to effect in organs with high energy demand, like the myocardium, and mitochondrial cardiomyopathy is a well-recognized entity [@bb0080], [@bb0085]. Not surprisingly, mitochondrial dysfunction has been associated with cardiomyopathy [@bb0090], [@bb0095] and mutations in the mitochondrial genome affecting tRNA have been identified in individuals with DCM [@bb0100], [@bb0105].

Mitochondrial DNA is solely maternally inherited in most instances [@bb0110], and in this family, as two of four children have been identified with homoplasmic mutations, the laboratory interpretation (personal discussion with Baylor Miraca Genetics Laboratories) is that there is a probability of maternal homoplasmy as well. The mutation in the tRNA Cys, found in our patients has been reported in other patients with encephalomyopathy and mitochondrial myopathy, Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-like episodes (MELAS), hearing loss as well as asymptomatic family members [@bb0115], [@bb0120], [@bb0125]. As SNHL was present in both our patient and her sister who did not have the long QT mutation, we feel that the mitochondrial tRNA Cys change is the underlying etiology.

Additionally, we feel that the mitochondrial mutation may have contributed to or even potentiated the clinical presentation of cardiomyopathy and the seemingly complete remission after prolonged and intensive cardiac support ([Fig. 1](#f0010){ref-type="fig"}). There are reports of a child with both long QT and hypertrophic cardiomyopathy mutations as well as a child with same tRNA Cys mutation who hypertrophic cardiomyopathy and mitochondrial myopathy [@bb0130], [@bb0135], but none of a patient or family similar to ours.

WES also allows the determination of the parent of origin in the case of inherited mutations. All family members carrying either mutation have been recommended to undergo routine clinical screening along with genetic testing. Screening offered to family members included echocardiography and EKGs.

The exact cause of the sudden cardiac death in the older sister is unclear. It is quite possible that she also carried the same mutations or variants in mitochondrial tRNA Cys, MYBPC3, KCNH2, or a combination of more than one. Post-mortem genetic testing could have potential benefit for the family [@bb0130], though was not possible in this case. Nevertheless, information regarding both the mechanisms and related risks to all surviving family members may prove to be invaluable for their health.

5. Conclusions {#s0025}
==============

As we continue to accumulate information on variants found by whole exome sequencing, it is likely that we will be able to better classify them as benign or pathogenic. While mutations in any one of these three genes can convey pathogenicity in a variable manner, it is clear that in combination, initial cardiac stress also became a risk for both rhythm disturbances and dilated cardiomyopathy, ultimately leading to functional compromise. The identification of the two individual gene mutations via clinical testing may have provided an initial clue, but not the full physiologic phenotype for this child\'s cardiac risks and intermingled pathology ([Fig. 2](#f0015){ref-type="fig"}). Multiple episodes of full cardiac support via ECMO allowed the myocardium to rest but the underlying genetic risks to metabolic stress may have ultimately led to this child\'s passing. We also feel that it is important to consider the possible contribution of the sequence variation in MYBPC3, as may also have potentiated pathogenicity under the unique circumstance of mitochondrial compromise and arrhythmia.

This case demonstrates that multiple underlying genetic mechanisms should be considered in extraordinary clinical presentations. We offer that multiple genetic mutations and/or variants of unclear significance may be acting synergistically to compound phenotype. Thoughtful identification can have a profound effect upon both the patient\'s care and counseling to other family members regarding their own health risks.

 {#s0030}
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![1--3: Initial presentation in congestive heart failure. (2) and (3) were obtained prior to placement on ECMO after rapidly worsening cardiac function. (1) Mildly dilated left atrium and ventricle. (2) parasternal short axis image showing minimal motion of the interventricular septum and excursion of the posterior wall, suggesting severely decreased left ventricular function. The calculated shortening fraction (SF) was 10% (normal range 28--40%). (3) Apical 4 chamber view showing generalized dilatation with thin left ventricular walls, consistent with dilated cardiomyopathy (DCM). The left ventricle also shows mild hypertrabeculation of the posterior wall which can represent non-compaction of the left ventricle. There is a thrombus in the right atrium (shown with the arrow). Images 4 and 5 were obtained between hospitalizations and show complete echocardiographic resolution of her failed systolic function. (4) Parasternal short axis view showing a thicker ventricular septum and posterior walls more consistent with non-compaction/hypertrophic cardiomyopathy (HCM) when compared with (2). Note the normal excursion of both walls. SF was 37%. (5) Apical 4 chamber view showing normal systolic function and significant hypertrabeculation.](gr1){#f0010}

![The 3 pathogenic mutations and their interaction in the heart are depicted. Loss of function mutations in KCNH2 and a membrane potassium channel are associated with long QT syndrome type 2 (LQTS2). In LQTS2 loud noises can trigger torsades de pointes, ultimately leading to syncope, seizures or sudden cardiac death. Cardiac myosin-binding protein C, encoded by MYBPC3, binds myosin and when phosphorylated mediates contraction. The mytochondrial transfer RNA-cysteine (tRNACys) localizes within the mitochondria and abnormal synthesis of mitochondrial proteins and/or oxidative stress imbalances have been associated with DCM [@bb0100]. We postulate that abnormalities in cardiac myosin-binding protein C were responsible for the dilated cardiomyopathy present in our patient and the mitochondrial dysfunction secondary to the mutation in the tRNACys had an additive effect on the severity of the phenotype.](gr2){#f0015}

###### 

Results of WES clinical testing (Baylor, Molecular Diagnostics Laboratory) in the initial proband.

  Gene                                       Protein                                            Function                                                                               Position          Isoform     Location   Variant (amino acid)   Variant (protein)   Genbank accession numbers   Parent of origin   Pathogenicity       Predicted phenotype                         Polyphen/SiFT   Polymorphism or ESP5400 status
  ------------------------------------------ -------------------------------------------------- -------------------------------------------------------------------------------------- ----------------- ----------- ---------- ---------------------- ------------------- --------------------------- ------------------ ------------------- ------------------------------------------- --------------- --------------------------------
  *Mutations per initial clinical reports*                                                                                                                                                                                                                                                                                                                                                                
  MYBPC3                                     Myosin binding protein C                           Binds myosin to modulate contraction                                                   Chr11:47367777    NM_000256   Exon 11    c\. 1071C\>T           p.Arg358X           ENSG00000134571             Mother             Likely pathogenic   HCM/DCM                                     NA/NA           Not reported
  KCNH2                                      Membrane potassium channel                         Potassium flow during repolarization                                                   Chr7:150647150    NM_172058   Exon 9     c.2503del C            p.Leu835fs          ENSG0000055118              Father             Likely pathogenic   LQTS2                                       NA/NA           Not reported
  MT-TC                                      tRNA Cys                                           Mitochondrial cysteine transport                                                                                                m.5814T\>C                                 HGNC:7477                   Mother             Pathogenic          Mitochondrial myopathy MELAS asymptomatic                   
                                                                                                                                                                                                                                                                                                                                                                                                          
  *Variants*                                                                                                                                                                                                                                                                                                                                                                                              
  MYPN                                       Myopalladin                                        Interacts with nebullete in cardiac muscle and nebulin in skeletal muscle in Z-lines   Chr10:69934085    NM_032578   Exon 11    c.2236A\>G             p.Thr746Ala                                     Mother             VUS                 DCM/HCM                                                     rs147287437
  TTN                                        Titin                                              Major component in striated muscle                                                     Chr2:179455631    NM_133378   Exon 253   c.53117C\>T            p.Pro177706Leu      ENSG00000155657             Father             VUS                 CM, MD, myopathy                                            ESP5400
  TTN                                        Titin                                              Major component in striated muscle                                                     Chr2:179449188    NM_133378   Exon 260   c.57388C\>T            p.Arg19130Cys       ENSG00000155657             Father             VUS                 CM, MD, myopathy                                            ESP5400
  TTN                                        Titin                                              Major component in striated muscle                                                     Chr2:179603991    NM_003319   Exon 45    c.12880A\>C            p.Asn4294HIs        ENSG00000155657             Father             VUS                 CM, MD, myopathy                                            ESP5400
  TTN                                        Titin                                              Major component in striated muscle                                                     Chr2:179585257    NM_133378   Exon 77    c.19500C\>G            p.Asn6500Lys        ENSG00000155657             Father             VUS                 CM, MD, myopathy                                            ESP5400
  TTN                                        Titin                                              Major component in striated muscle                                                     Chr2: 179612873   NM_133379   Exon 46    c.14254A\>C            p.Ser4752Arg        ENSG00000155657             Mother             VUS                 CM, MD, myopathy                                            rs146504870
  COG6                                       Component of the oligomeric Golgi complex 6        Component of the conserve oligomeric Golgi complex                                     Chr13:40235007    NM_020751   Exon 3     c.358A\>G              p.Ser120Gly         ENSG00000133103                                VUS                 CDG III                                                     rs139313781
  GIPC3                                      GIPC PDZ domain containing family                  Role in hair bundle survival                                                           Chr19:3590081     NM_133261   Exon 6     c.832G\>A              p.Glu278Lys         ENSG00000179855             Novel              VUS                 Deafness AR15                                               Novel
  MED23                                      Mediator complex subunit 23                        Role in identification of enhancer sites in DNA for transcription                      Chr6:131908846    NM_004830   Exon 29    c.4080G\>T             p.Val1360Val        ENSG00000112282                                VUS                 Intellectual disability (AR 18)                             rs138742804
  LAMA2                                      Laminin                                            Component of basement membrane                                                         Chr6:129759787    NM_000426   Intronic   c.5969-4G\>A                               ENSG00000196569             Novel              VUS                 MD (Merosin)                                                Novel
  UPF3B                                      UPF3 regulator of nonsense transcripts homolog B   Regulates post-splicing multiprotein complex                                           ChrX:118971901    NM_080632   Exon 10    c.1121G\>A             p.Arg374His         ENSG00000125351             Father             VUS                 Intellectual disability (X-linked 14)                       rs143538947
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